Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Amir S. Kamran

Hematology Oncology
Charleston Area Medical Center Inc
3415 Maccorkle Ave Se, 
Charleston, WV 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Advanced in WT1-Related Wilms Tumor Syndromes
Charleston Area Medical Center Inc
3415 Maccorkle Ave Se, 
Charleston, WV 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amir Kamran is a Hematologist Oncology provider in Charleston, West Virginia. Dr. Kamran is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), and WT1-Related Wilms Tumor Syndromes. Dr. Kamran is currently accepting new patients.

His clinical research consists of co-authoring 21 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in WV
Hospital Affiliations
Charleston Area Medical Center
Logan Regional Medical Center
Boone Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Dominion National
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

CHARLESTON AREA MEDICAL CENTER INC
3415 Maccorkle Ave Se, Charleston, WV 25304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Other
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin acetate, Histrelin acetate, Leuprolide acetate, Nilutamide, Prednisone, Triptorelin
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

21 Total Publications

177Lu-vipivotide tetraxetan (PSMA-617) vs cabazitaxel in metastatic castration-resistant prostate cancer: a real-world analysis using the TriNetX database.
177Lu-vipivotide tetraxetan (PSMA-617) vs cabazitaxel in metastatic castration-resistant prostate cancer: a real-world analysis using the TriNetX database.
Journal: International urology and nephrology
Published: May 13, 2025
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Galena Salem
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Galena Salem
Hematology Oncology | Hematology | Oncology

Kings Daughters Medical Specialties Inc

2201 Lexington Ave, 
Ashland, KY 
 (56.9 miles away)
606-408-4000
Languages Spoken:
English, Russian, Ukrainian
See accepted insurances
Accepting New Patients

Galena Salem is a Hematologist Oncology specialist and a Hematologist in Ashland, Kentucky. Dr. Salem is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Large-Cell Immunoblastic Lymphoma, Non-Hodgkin Lymphoma, Familial Colorectal Cancer, Clear Cell Sarcoma, and Bone Marrow Transplant. Dr. Salem is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Arvinder S. Bir
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Arvinder S. Bir
Hematology Oncology | Hematology | Oncology

St. Mary's Himg, LLC

5170 Us Route 60, 
Huntington, WV 
 (40.6 miles away)
304-528-4600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Arvinder Bir is a Hematologist Oncology specialist and a Hematologist in Huntington, West Virginia. Dr. Bir is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Bir is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Mark E. Pajeau
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Mark E. Pajeau
Hematology Oncology | Hematology | Oncology

Holzer Clinic LLC

170 Jackson Pike, 
Gallipolis, OH 
 (49.6 miles away)
740-446-5474
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Pajeau is a Hematologist Oncology specialist and a Hematologist in Gallipolis, Ohio. Dr. Pajeau is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Large-Cell Lung Carcinoma. Dr. Pajeau is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kamran's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 52 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile